Details of the Drug Pharmacogenomic Perturbation Atlas

Gemifloxacin Drug Info

Factiv; Factive; Gemifloxacin [INN]; Gemifloxacin mesilate; LB 20304; LB 20304a; SB 265805; Factiv (TN); Factive (TN); Gemifloxacin (INN); LB-20304; SB-265805; 7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid; 7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid

Therapeutic Class

Antibiotics

Cross-matching ID

PubChem CID

9571107

ChEBI ID

CHEMBL430

CAS Number

CAS 175463-14-6

TTD Drug ID

D0VR7W

VARIDT Drug ID

DR00688

ACDINA Drug ID

D00301

General Information of Drug (ID: DMHT34O)

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Mitophagy	-1.70	4.02e-2	56/68 (82.35%)	TBC1D15;TBK1;GABARAPL2;...
Fatty acid degradation	-1.72	3.55e-2	40/43 (93.02%)	ACSL6;ACADVL;ACAT1;...
Steroid biosynthesis	-1.72	3.95e-2	19/20 (95%)	DHCR7;MSMO1;SQLE;...
Retinol metabolism	-1.72	4.44e-2	41/68 (60.29%)	CYP2C9;UGT2B28;DGAT1;...
Inflammatory bowel disease	-1.75	3.43e-2	58/65 (89.23%)	TLR2;STAT4;TNF;...
Malaria	-1.76	3.84e-2	44/50 (88%)	TLR2;TNF;SELE;...
Peroxisome	-1.77	3.65e-2	72/82 (87.8%)	MPV17;PEX3;EHHADH;...
Bladder cancer	-1.77	4.32e-2	40/41 (97.56%)	RPS6KA5;SRC;CDKN2A;...
Protein digestion and absorption	-2.01	3.20e-3	78/103 (75.73%)	MEP1A;DPP4;ATP1A2;...
Collecting duct acid secretion	-2.07	4.80e-3	22/27 (81.48%)	ATP6V1B2;ATP6V1F;ATP6V0D1;...
Mineral absorption	-2.34	0.00e+0	48/60 (80%)	FXYD2;ATP7B;SLC39A4;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H

Breast

Breast adenocarcinoma

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	24H

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	24H

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	24H

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.01uM - 10uM	24H

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.01uM - 10uM	24H

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	24H

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	24H

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 3.33uM	24H